These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3380061)

  • 1. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
    Vredenburgh JJ; McIntyre OR; Cornwell GG; Ball ED; Cornell CJ; Mills LE; O'Donnell JF
    Med Pediatr Oncol; 1988; 16(3):187-9. PubMed ID: 3380061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
    Larson RA; Daly KM; Choi KE; Han DS; Sinkule JA
    J Clin Oncol; 1987 Mar; 5(3):391-7. PubMed ID: 3546616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
    Paciucci PA; Davis RB; Holland JF; Martelo O; Schiffer CA
    Am J Clin Oncol; 1990 Dec; 13(6):516-9. PubMed ID: 2239806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
    Kaminer LS; Choi KE; Daley KM; Larson RA
    Cancer; 1990 Jun; 65(12):2619-23. PubMed ID: 2340463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone for refractory and relapsed acute leukemia.
    Bezwoda WR; Bernasconi C; Hutchinson RM; Winfield DA; de Bock R; Mandelli F
    Cancer; 1990 Aug; 66(3):418-22. PubMed ID: 2194640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
    Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
    Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia.
    Schulman P; Davis R; Lee E; Ellerton J; Staszweski H
    Cancer Treat Rep; 1987; 71(7-8):755-7. PubMed ID: 3607786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.
    Lin MT; Chen YC; Liu TW; Tien HF; Liu MC; Wang CH; Shen MC; Liu CH
    Taiwan Yi Xue Hui Za Zhi; 1989; 88(11-12):1116-22. PubMed ID: 2636248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
    Goldberg J; Gryn J; Raza A; Bennett J; Browman G; Bryant J; Grunwald H; Larson R; Vogler R; Preisler H
    Am J Hematol; 1993 Aug; 43(4):286-90. PubMed ID: 7690519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
    Amrein PC; Davis RB; Mayer RJ; Schiffer CA
    Am J Hematol; 1990 Oct; 35(2):80-3. PubMed ID: 2399909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II trial of mitoxantrone in acute leukemia.
    Arlin ZA; Silver R; Cassileth P; Armentrout S; Gams R; Daghestani A; Coleman M; Schoch I; Dukart G
    Cancer Treat Rep; 1985 Jan; 69(1):61-4. PubMed ID: 3855386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone in refractory acute leukemia in children: a phase I study.
    Starling KA; Mulne AF; Vats TS; Schoch I; Dukart G
    Invest New Drugs; 1985; 3(2):191-5. PubMed ID: 4019122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia.
    Mailliard JA; Letendre L; Dalton RJ; Levitt R; Gerstner JB; Therneau TM; Pierre RV
    Med Pediatr Oncol; 1986; 14(6):306-9. PubMed ID: 3466001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
    Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.